2,575 Shares in Humana Inc. (NYSE:HUM) Purchased by OVERSEA CHINESE BANKING Corp Ltd

Key Points

• OVERSEA CHINESE BANKING Corp Ltd acquired 2,575 shares of Humana Inc. valued at approximately $696,000 during the first quarter.
• Humana's recent earnings report showed a miss in EPS at $6.27 compared to expectations of $6.32, despite a revenue increase to $32.39 billion.
• The stock currently has a consensus rating of "Hold" among analysts, with an average price target of $281.62.

OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,575 shares of the insurance provider's stock, valued at approximately $696,000.

Other large investors have also recently made changes to their positions in the company. Shufro Rose & Co. LLC purchased a new stake in Humana in the 1st quarter valued at about $210,000. Sound View Wealth Advisors Group LLC boosted its position in Humana by 5.8% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,154 shares of the insurance provider's stock valued at $305,000 after buying an additional 63 shares during the period. Modera Wealth Management LLC purchased a new stake in Humana in the 1st quarter valued at about $230,000. Arkadios Wealth Advisors purchased a new stake in Humana in the 1st quarter valued at about $258,000. Finally, Bayforest Capital Ltd boosted its position in Humana by 803.1% in the 1st quarter. Bayforest Capital Ltd now owns 4,416 shares of the insurance provider's stock valued at $1,168,000 after buying an additional 3,927 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Trading Down 1.1%

NYSE HUM opened at $247.19 on Monday. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $29.73 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 1.45 and a beta of 0.44. The company has a 50 day moving average price of $235.09 and a 200 day moving average price of $254.92. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $382.72.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The company's revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm earned $6.96 EPS. As a group, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company set a $348.00 price objective on shares of Humana in a research report on Friday, July 18th. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Truist Financial lowered their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. Finally, Barclays set a $275.00 price objective on shares of Humana and gave the company an "equal weight" rating in a research note on Thursday. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Humana has a consensus rating of "Hold" and an average price target of $281.62.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.